Kazia Therapeutics Limited (KZIA) Bundle
An Overview of Kazia Therapeutics Limited (KZIA)
General Summary of Kazia Therapeutics Limited (KZIA)
Kazia Therapeutics Limited is a biotechnology company focused on developing innovative oncology therapeutics. Headquartered in Sydney, Australia, the company specializes in developing advanced cancer treatments.
| Company Metric | 2024 Details |
|---|---|
| Founded | 2003 |
| Stock Exchange Listing | NASDAQ (KZIA) |
| Primary Research Focus | Oncology Drug Development |
Key Product Portfolio
- GDC-0084: Brain cancer therapeutic
- Paxalisib: Precision oncology drug
- EVT-801: Ovarian cancer treatment
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $3.2 million |
| Research & Development Expenses | $12.5 million |
| Net Loss | $9.3 million |
Industry Leadership
Kazia Therapeutics demonstrates significant potential in oncology drug development, with multiple clinical-stage assets targeting critical unmet medical needs.
- Advanced clinical trials in brain cancer
- Precision oncology platform
- Strategic partnerships with research institutions
Mission Statement of Kazia Therapeutics Limited (KZIA)
Mission Statement of Kazia Therapeutics Limited (KZIA)
Kazia Therapeutics Limited (KZIA) focuses on developing innovative oncology therapeutics targeting aggressive brain cancers and other challenging tumor types.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Drug Development | Precision oncology therapeutics | 2 primary drug candidates in clinical trials |
| Research Targeting | Glioblastoma and brain metastases | GDC-0084 and PAXWAVE programs |
| Clinical Progress | Advanced stage oncology research | Phase 2/3 clinical trial stages |
Research Focus Areas
- GDC-0084 for glioblastoma treatment
- PAXWAVE for brain metastases
- Precision molecular targeting strategies
Clinical Development Metrics
As of 2024, Kazia Therapeutics demonstrates significant research commitment:
- Research investment: $12.3 million annually
- Clinical trial expenditure: $8.7 million
- Active clinical trials: 3 ongoing programs
Financial Research Investment
| Category | 2024 Allocation |
|---|---|
| R&D Expenditure | $12.3 million |
| Clinical Trial Budget | $8.7 million |
| Drug Development Cost | $5.6 million |
Strategic Oncology Objectives
Kazia Therapeutics prioritizes innovative cancer treatment solutions through targeted molecular research approaches.
Vision Statement of Kazia Therapeutics Limited (KZIA)
Vision Statement of Kazia Therapeutics Limited (KZIA)
Innovative Oncology Research FocusKazia Therapeutics Limited (KZIA) demonstrates a strategic vision centered on developing innovative therapeutic solutions for challenging cancer treatments, specifically targeting rare and difficult-to-treat cancer types.
Key Research Priorities
Primary Therapeutic Targets| Cancer Type | Research Focus | Current Development Stage |
|---|---|---|
| Glioblastoma | GDC-0084 Clinical Trials | Phase II Clinical Studies |
| Pancreatic Cancer | Paxalisib Investigational Therapy | Ongoing Clinical Investigations |
Strategic Research Objectives
- Advance precision oncology drug development
- Target molecular mechanisms in rare cancer types
- Accelerate clinical translation of innovative therapeutics
| Research Expenditure (2023) | Amount |
|---|---|
| Total R&D Spending | $7.2 Million |
| Clinical Trial Investments | $4.5 Million |
Global Research Collaboration Strategy
KZIA maintains strategic partnerships with international research institutions to enhance therapeutic development capabilities.
- Collaborative research networks
- Cross-institutional clinical trial partnerships
- Global knowledge exchange platforms
Core Values of Kazia Therapeutics Limited (KZIA)
Core Values of Kazia Therapeutics Limited (KZIA)
Innovation and Scientific Excellence
Kazia Therapeutics demonstrates commitment to innovation through its focused research in oncology drug development.
| R&D Investment | 2023 Amount |
|---|---|
| Total R&D Expenditure | $6.8 million |
| Percentage of Revenue | 87.3% |
Patient-Centric Approach
The company prioritizes patient needs in oncology research and clinical trials.
- GDC-0084 clinical trials for brain cancer patients
- Paxalisib ongoing clinical development
- Focus on rare and difficult-to-treat cancers
Ethical Research and Transparency
Commitment to transparent clinical research practices.
| Clinical Trial Metrics | 2023-2024 Data |
|---|---|
| Active Clinical Trials | 3 ongoing trials |
| Registered Clinical Trials | 5 registered studies |
Collaborative Scientific Approach
Engagement with global research institutions and pharmaceutical partnerships.
- Collaboration with MD Anderson Cancer Center
- Partnership with Dana-Farber Cancer Institute
- International research network participation
Sustainable Corporate Responsibility
Commitment to sustainable research practices and corporate governance.
| Corporate Sustainability Metrics | 2023 Performance |
|---|---|
| Corporate Governance Score | 7.2/10 |
| Environmental Compliance Rating | A- |
Kazia Therapeutics Limited (KZIA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.